---
title: >-
  Comparing PCSK9 Monoclonal Antibody Treatment Strategies Following Myocardial
  Infarction Using Negative Control Outcomes: A Target Trial Emulation Study.
description: >-
  Explore this publication on real-world evidence: Comparing PCSK9 Monoclonal
  Antibody Treatment Strategies Following Myocardial Infarction Using Negative…
date: '2024-01-01'
category: Publications
tags:
  - Epidemiology
  - Abstract / Manuscript
  - R&D
  - Care
  - Methods/Pharmacoepi
  - Cardiovascular
  - Health System Partner
canonical_url: >-
  https://www.pedestalhealth.com/resources/publications/epidemiology/comparing-pcsk9-monoclonal-antibody-treatment-strategies/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: comparing-pcsk9-monoclonal-antibody-treatment-strategies
id: 2mrpfu9qA92vjCn8jbKMJv
contentType: article
---

## Challenge

Real-world comparative effectiveness of PCSK9 inhibitor treatment strategies following MI had not been established using rigorous causal methods that account for dynamic treatment decisions and unmeasured confounding.

## Solution

Target RWE researchers applied negative control outcomes within a target trial emulation framework to compare PCSK9 monoclonal antibody treatment strategies in post-MI patients, leveraging NCOs to assess confounding control before estimating effectiveness.

## Impact

Demonstrating valid real-world comparative effectiveness of PCSK9 inhibitors following MI using NCO gating and target trial emulation provides pharma partners with regulatory-credible evidence for this high-value cardiovascular indication.